Use access key #2 to skip to page content.

JimVanMeerten (62.86)

3 Hot Nasdaq stock to put on your watch list -- 12/8

Recs

3

December 08, 2010 – Comments (0) | RELATED TICKERS: PARL.DL , TXRH , SNTA

Here are 3 NASDAQ stocks that hit the most frequent new high onBarchart.  Try these for your watch list.

PARL - Parlux Fragrances - a manufacturer and international distributor of prestige products. It holds licenses for Paris Hiltonfragrances, watches, cosmetics, sunglasses, handbags and other small leather accessories in addition to licenses to manufacture and distribute the designer fragrance brands of Perry Ellis, XOXO, Ocean Pacific, Maria Sharapova, Andy Roddick, babyGund, and Fred Hayman Beverly Hills.

Paris Hilton? That's hot!!

1 - 96% Barchart technical buy signal

2 - 18 new highs in the last month

3 - Up 11.63% in the last month

4 - Relative Strength Index 70.60% and rising

5 - Trading around 2.80 which is above it's 50 day moving average of 2.66

TXRH - Texas Roadhouse -a growing, moderately priced, full service restaurant chain. They offer an assortment of specially seasoned and aged steaks hand-cut daily in every restaurant and cooked to order over open gas-fired grills. They also offer their customers, whom they call their guests, a selection of ribs, fish, chicken and vegetable plates, an assortment of hamburgers, salads and sandwiches.

1 - 96% Barchart technical buy signal

2 - 16 new highs in the last month

3 - Up 12.97% in the last month

4 - Relative Strength Index 81.99% and rising

5 - Trading around 18.20 which is above its 50 day moving average of 15.88

SNTA - Synta Pharmaceuticals -a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and drug discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma.

1 - 100% Barchart technical buy signal

2 - 16 new highs in the last month

3 - Up 49.58% in the last month

4 - Relative Strength Index 87.53

5 - Trading around 5.35 which is above its 50 day moving average of 3.95 

Jim Van Meerten is an advisor to Marketocracy Capital Managementwho uses his model portfolios not only to manage their mutual funds but also their clients Separately Managed Accounts. You can read his blogs about those model portfolios and investing here and on Barchart Portfolio Blogs. Please leave a comment below or emailJimVanMeerten@gmail.com.

Disclosure: Jim Van Meerten through Marketocracy Capital Management has an interest in the stocks mentioned in this blog. 

0 Comments – Post Your Own

Featured Broker Partners


Advertisement